Effects of Sacubitril valsartan sodium combined with Metoprolol in treatment of patients with dilated cardiomyopathy
Objective:To observe effects of Sacubitril valsartan sodium combined with Metoprolol in treatment of patients with dilated cardiomyopathy.Methods:A prospective study was conducted on 100 patients with dilated cardiomyopathy admitted to the hospital from March 2021 to March 2023.According to the random number table method,they were divided into study group and control group,50 cases in each group.The control group was treated with Metoprolol,while the study group was treated with Sacubitril valsartan sodium on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],myocardial injury markers[cardiac troponin I(cTnI),acid kinase isoenzyme(CK-MB),N-terminal pro-brain natriuretic peptide(NT-proBNP),endothelin-1(ET-1)]and inflammatory indexes[transforming growth factor-β1(TGF-β1),soluble intercellular adhesion molecule-1(sICAM-1),tumor necrosis factor-α stimulating gene-6(TSG-6)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 88.00%(44/50),which was higher than 70.00%(35/50)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of LVESD and LVEDD in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant(P<0.05).The levels of cTnI,CK-MB,NT-proBNP and ET-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of TGF-β1,sICAM-1 and TSG-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril valsartan sodium combined with Metoprolol in the treatment of the patients with dilated cardiomyopathy can improve the total effective rate of treatment,improve the levels of cardiac function indexes,and reduce the levels of myocardial injury markers and inflammatory indexes.Moreover,it is superior to single Metoprolol treatment.
NETL
NSTL
万方数据
